Ubs Group Ag Annovis Bio, Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 48,736 shares of ANVS stock, worth $108,681. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,736
Previous 1,847
2538.66%
Holding current value
$108,681
Previous $14,000
1650.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ANVS
# of Institutions
48Shares Held
1.56MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA466KShares$1.04 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$479,9110.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$224,5810.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$222,0270.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$219,6900.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.2M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...